Creatine Effect on Brown Adipose Tissue Activation (CreaBAT)

February 22, 2021 updated by: Patrick Schrauwen, Maastricht University

Creatine Monohydrate Supplementation in Young, Healthy Vegetarian Adults and Its Effect on Brown Adipose Tissue Activation

Pre-clinical studies indicate that creatine may play a substantial role in diet-induced thermogenesis and may have a profound effect on energy balance. A recent retrospective study of BAT activation on PET-CT scans in humans showed a positive association with the estimated renal creatinine clearance and BAT activation, possibly linking creatine metabolism in humans to BAT activity. In humans, so far little options are available to activate brown adipose tissue. The most potent intervention to activate BAT is via cold, which has previously been shown to have metabolic effects in humans. Provided the potential health benefits of brown adipose tissue activation in humans, and provided the role of brown fat in diet induced thermogenesis, we here aim to determine whether creatine monohydrate supplementation can increase diet-induced thermogenesis and activate brown adipose tissue in humans.

Study Overview

Study Type

Interventional

Enrollment (Actual)

14

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Limburg
      • Maastricht, Limburg, Netherlands, 6229ER
        • Maastricht University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years to 28 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Male or female;
  • 18 to 30 years of age;
  • Consuming a vegetarian diet;
  • BMI 20-25 kg/m2.

Exclusion Criteria:

  • Not meeting all inclusion criteria;
  • Non-vegetarian diet;
  • Excessive alcohol and/or drug abuse;
  • Significant allergies or intolerances concerning the study products;
  • Participation in another biomedical study within 1 month before the first study visit, possibly interfering with the study results;
  • Medication use known to hamper subject's safety during the study procedures;
  • Subjects with contra-indications for MRI and/or PET-CT;
  • Subjects who do not want to be informed about unexpected medical findings;
  • Subjects who do not want that their treating physician to be informed;
  • Co-morbidities to which the intervention or program that may pose as a complicating factor;
  • Inability to participate and/or complete the required measurements;
  • PET-CT scan in the last 12 months.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Intervention
Oral injestion of 20 grams of creatine monohydrate daily
5 grams of creatine monohydrate, four times daily, for 9 consecutive days.
Placebo Comparator: Placebo
Oral injestion of 20 grams of cellulose daily
oral ingestion of placebo containing 20 gram cellulose daily

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Brown adipose tissue activation through 18F-FDG PET-MRI
Time Frame: Day 10 of protocol
Standard Uptake Value (SUV)
Day 10 of protocol

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Diet-induced thermogenesis through indirect calorimetry
Time Frame: Day 8 of protocol
Whole body energy expenditure in kJ/kg/min
Day 8 of protocol
Posphocreatine (PCr) Recovery through 31P-MRS
Time Frame: Day 9 of protocol
Halftime of PCr Recovery
Day 9 of protocol

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 1, 2018

Primary Completion (Actual)

January 22, 2020

Study Completion (Actual)

January 22, 2020

Study Registration Dates

First Submitted

September 10, 2019

First Submitted That Met QC Criteria

September 10, 2019

First Posted (Actual)

September 11, 2019

Study Record Updates

Last Update Posted (Actual)

February 24, 2021

Last Update Submitted That Met QC Criteria

February 22, 2021

Last Verified

February 1, 2021

More Information

Terms related to this study

Other Study ID Numbers

  • NL64709.068.18

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Diet-induced Thermogenesis

Clinical Trials on Creatine monohydrate

3
Subscribe